• A.D.A.M (Atlanta) reported the introduction of the A.D.A.M. symptom navigator web application for the iPhone. This interactive tool helps consumers match medical symptoms with relevant assessments and appropriate treatments. A.D.A.M. engineered this web application version of its Symptom Navigator for optimal display on the iPhone, taking full advantage of its multi-touch interface. Using the symptom navigator, consumers are presented with an image of the human body and they click on the affected area of the body to receive a menu of related symptoms. After selecting a symptom, the user is walked through the possible causes, home care, when to consult your doctor, and what to expect from your doctor. This data is provided by A.D.A.M. from their medically reviewed, evidence-based and URAC accredited health encyclopedia. A.D.A.M. makes health information.

• Alma Lasers (Las Vegas) reported FDA clearance for the Harmony, its newest platform for multiple aesthetic laser and light treatments. The Harmony can be used to treat more than 60 popular aesthetic indications and applications, including acne, skin rejuvenation, hair removal, varicose veins, stretch marks, tattoo removal, wrinkles and skin tightening. The Harmony combines lasers, pulsed light, near-infrared, LED and UVB technologies with multiple exchangeable handpieces to ensure easy and effective singular and combined therapeutic treatment. Alma Lasers makes laser, light, and radiofrequency-based aesthetic devices.

• Applied Biosystems (Foster City, California) and its joint-venture partner, MDS Analytical Technologies, a business unit of MDS, reported the availability of a suite of integrated mass spectrometry-based solutions for conducting targeted quantitative proteomics studies. Designed for Applied Biosystems/MDS Analytical Technologies' triple quadrupole and hybrid triple quadrupole/linear ion trap mass spectrometry systems, these solutions include software packages and consumables that help scientists to quantify proteins in biomarker research or cell biology. Through a joint venture with MDS Analytical Technologies, Applied Biosystems makes products for the mass spectrometry market, based on industry-leading platforms, software and new application workflows.

• Braemar (Minneapolis) has introduced the DL900, a digital Holter monitor. The monitor weighs 1.75 ounces, and has extended recording time of up to seven days. A newly designed, custom analog IC for signal acquisition is the technology platform for the advanced capabilities of the DL900. The device combines high-speed USB transfer capability with the ability to use a removable SD memory card. The DL900 provides high-resolution recordings as well as high sampling rate options suitable for both clinical and research applications. A programmable pacemaker detection capability provides the clinician with additional data. Braemar makes cardiac monitoring devices.

• Lutronic (Princeton Junction, New Jersey) said that it has received FDA clearance to market its Spectra VRM III. This dual-pulse, Q-Switched Nd:Yag laser is the successor to the Spectra VRM II. The laser produces 4 wavelengths (1064 nm, 532 nm, 585 nm, 650 nm) in Q-switched nanosecond pulse. It is specifically designed to treat a wide array of dermatological and aesthetic conditions, including dermal and epidermal pigmented lesions, multicolor tattoos, melasma, and active acne. It further enables laser toning, and non-ablative photo-acoustic skin rejuvenation techniques.The laser uses a dual pulse mode, which enables it to produce very short and quasi-long microsecond pulses. Lutronic makes medical laser systems.

• Momentive Performance Materials (Wilton, Connecticut) has introduced the StatSil elastomer, made using a new technology that provides built-in antimicrobial protection in silicone-based elastomers. StatSil elastomer should be used only to control the growth of microbes in or on the human body; it should not be used to provide general public health benefits. Momentive Performance Materials is a specialty materials company.

• Urologix (Minneapolis) reported long-term clinical results from a multi-center trial with the Urologix Cooled ThermoCath (CTC) microwave catheter for treatment of benign prostatic hyperplasia (BPH), also known as enlarged prostate. The therapy is delivered in a physician's office with a treatment time of under 30 minutes. The results showed the efficacy of the CTC microwave catheter is durable for at least five years and the freedom from additional minimally invasive or surgical procedures is 90%. The data from the study showed clinically significant improvement from baseline of the three major BPH evaluation criteria: urinary flow rate, symptom improvement, and quality of life at five-year follow-up. Urologix makes minimally invasive medical products for the treatment of urological disorders.

• ViraCor Laboratories (Kansas City, Missouri) reported the launch of a new enterovirus test that quickly pinpoints the virus. The molecular test quickly and accurately detects the more than 70 known strains of enterovirus, giving physicians the information they need to treat patients appropriately. It also allows them to determine and track the severity of an infection by measuring a patient's viral load. The enterovirus test is one of 21 infectious disease tests ViraCor provides to healthcare professionals who care for patients with compromised immune systems, including adults and children who are undergoing transplants or battling cancer.